Revisiting Interleukin-12 as a Cancer Immunotherapy Agent.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29549160.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0381.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. <i>Clin Cancer Res; 24(12); 2716-8. ©2018 AACR</i><i>See related article by Hu et al., p. 2920</i>.
Medical subject headings
- Interleukin-12
- Neoplasms